
Aardvark Therapeutics Faces Investor Lawsuit After Clinical Trial Halt
A 56% stock price collapse on March 2, 2026, has triggered a formal investigation into Aardvark Therapeutics. The shareholder rights firm Hagens Berman is probing whether the company misled investors regarding the safety and FDA communication status of its lead drug candidate, ARD-101, following a sudden halt to a key Phase 3 trial.






















